Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

cell leukemia that has come back or does not respond to treatment. High throughput screen tests many different drugs that kill multiple myeloma cells in individual chambers at the same time. Matching a

monoclonal protein
leukemia
bone marrow procedure
monoclonal antibodies
multiple myeloma
  • 13 views
  • 25 Jan, 2021
  • 1 location
Umbilical Cord Blood-Derived Natural Killer Cells Elotuzumab Lenalidomide and High Dose Melphalan Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

This phase II trial studies the side effects and best dose of umbilical cord blood-derived natural killer cells when given together with elotuzumab, lenalidomide, and high dose melphalan before autologous stem cell transplant and to see how well they work in treating patients with multiple myeloma. Before transplant, stem cells …

vasectomy
leukemia
chemotherapy regimen
multiple myeloma
tumor cells
  • 28 views
  • 24 Jan, 2021
  • 1 location
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

This phase I trial studies the safety of SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant together with sargramostim in treating patients with newly diagnosed multiple myeloma who are receiving lenalidomide maintenance therapy. Vaccines made from survivin peptide may help the body build an effective immune response to kill cancer cells …

induction therapy
colony stimulating factor
maintenance therapy
cancer
warfarin
  • 32 views
  • 06 Mar, 2021
  • 2 locations
Panobinostat Gemcitabine Hydrochloride Busulfan and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

This phase II trial studies how well panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell transplant work in treating patients with multiple myeloma that does not respond to treatment (refractory) or has returned (relapsed). Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed …

17p deletion
diffusion capacity of the lung for carbon monoxide
leukemia
bone marrow procedure
thalidomide
  • 0 views
  • 23 Jan, 2021
  • 1 location
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. …

blood cell count
antithymocyte globulin
leukemia
bone marrow procedure
remission
  • 64 views
  • 30 Jan, 2021
  • 1 location
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI).

pancytopenia
residual tumor
plasma cell leukemia
leukemia
bone marrow procedure
  • 146 views
  • 26 Jan, 2021
  • 1 location
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment. Single or double unit selected according to current University of Minnesota umbilical cord blood graft selection algorithm.

leukemia
chemotherapy regimen
hodgkin's disease
consolidation therapy
mantle cell lymphoma
  • 42 views
  • 25 Jan, 2021
  • 1 location
Allo HSCT Using RIC for Hematological Diseases

This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion. The primary objective is to evaluate rates of acute graft-versus-host disease (GVHD) grades II-IV and chronic GVHD with an updated GVHD prophylaxis of tacrolimus …

residual tumor
plasma cell leukemia
leukemia
bone marrow procedure
myelodysplasia
  • 27 views
  • 25 Jan, 2021
  • 1 location
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate …

pancytopenia
blood cell count
residual tumor
plasma cell leukemia
leukemia
  • 58 views
  • 27 Jan, 2021
  • 1 location
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma

Multiple Myeloma (MM) is a morbid disease associated with a poor outcome and while current therapies with new drugs have improved survival, MM still remains incurable in most patients. The only potential curative treatment remains allogeneic Hematopoietic stem cell transplant (HSCT), as shown by our cohort of 92 newly diagnosed …

measurable disease
plasma cell leukemia
leukemia
melphalan
bortezomib
  • 61 views
  • 05 Feb, 2021
  • 3 locations